Syros Pharmaceuticals announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros? Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023. Dr. Simonian will remain a member of the Syros Board of Directors following the transition.

Mr. Chee joined Syros in 2021. He was most recently at Novartis as Global Head of Oncology Portfolio Management, Global Pipeline Strategy and Precision Medicine. In this role, Mr. Chee contributed to shaping Novartis?

overall pipeline, including driving commercial planning for the company?s early-stage portfolio and diagnostics strategy for oncology. Earlier in his career at Novartis, Mr. Chee served as Vice President ? Global Head Oncology Lung Franchise, as well as in multiple US sales and marketing leadership roles.

During this time, his work included the U.S. launch of Afinitor, Zykadia, Signifor and the global launches of Tafinlar/Mekinist and Tabrecta. Prior to joining Novartis, Mr. Chee spent five years in roles of increasing responsibility at Pfizer, ultimately serving as Team Leader of International Business Development. He holds an M.B.A. from the Richard Ivey School of Business at the University of Western Ontario and a B.Sc.

Pharm. from the University of Alberta and completed his residency in Clinical Pharmacy at the University of British Columbia. In addition, and consistent with Syros?

strategic decision to invest its resources solely in advancing tamibarotene through late-stage clinical development to market, Eric Olson, Ph.D., Syros? Chief Scientific Officer since 2013, will depart Syros effective October 16, 2023.